BioPharma DiveOriginal article
GSK, Hansoh ADC extends survival in lung cancer study
Data ReadoutpositivePositive
AI Analysis
Summary
GSK and Hansoh reported that their ADC candidate extended survival in a lung cancer study, marking a first-in-class result for an ADC targeting the B7-H3 protein.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
ADC extended survival in lung cancer study, first for B7-H3 protein target
Importance:7/10
Sentiment:
0.70
ADClung cancerB7-H3GSKHansohsurvival benefit
Read the original article
Published by BioPharma Dive on July 10, 2026 3:42 PM